Solely final week, we reported on one of many few detrimental tales about semaglutide, a member of the category of medicine often called glucagon-like peptide 1 receptor agonists (GLP-1s or GLP-1RAs) which can be used to deal with diabetes and/or weight reduction.
It seems that the detrimental information cycle was short-lived. A brand new examine led by the Case Western Reserve College (CWRU) College of Drugs has added yet one more impact to the rising checklist of optimistic issues that GLP-1RAs can do: scale back the danger of obesity-associated cancers.
13 sorts of most cancers have been recognized as obesity-associated cancers (OAC): gallbladder, meningioma, pancreatic, liver (hepatocellular carcinoma), ovarian, colorectal, a number of myeloma, esophageal, endometrial, abdomen, breast, thyroid, and kidney. Weight problems and sort 2 diabetes additionally go hand-in-hand, and sufferers are prescribed GLP-1RA medicines to deal with both or each circumstances. Generally prescribed GLP-1RAs embrace semaglutide (Ozempic, Wegovy), liraglutide (Saxenda, Victoza) and dulaglutide (Trulicity).
The researchers examined the deidentified digital well being data of greater than 1.6 million US sufferers identified with sort 2 diabetes and prescribed GLP-1RAs or one other diabetes remedy (insulin or metformin) who had medical encounters with healthcare organizations between March 2005 and November 2018. None had a historical past of any of the 13 OACs. Examine contributors have been 47% feminine and included folks figuring out as American Indian or Alaskan Native, Asian, Black, Native Hawaiian or different Pacific Islander. The examine inhabitants was divided in line with every participant’s prescribed remedy for comparability (e.g., prescribed GLP-1RAs however not prescribed insulin vs insulin prescribed however not GLP-1RAs).
In contrast with insulin, GLP-1RAs have been related to a considerably decrease danger for 10 of the 13 OACs: gallbladder most cancers danger was diminished by 65%, meningioma by 63%, pancreatic most cancers by 59%, hepatocellular carcinoma by 53%, ovarian most cancers by 48%, colorectal most cancers by 46%, a number of myeloma by 41%, esophageal most cancers by 40%, endometrial most cancers by 26%, and kidney most cancers by 24%. There was no affiliation between GLP-1RAs and postmenopausal breast most cancers or thyroid most cancers. There was a discount in danger in relation to abdomen most cancers (27%), but it surely was not statistically important.
In contrast with metformin, GLP-1RAs have been related to a decreased danger of colorectal most cancers, gallbladder most cancers and meningiomas, but it surely was not statistically important. Nonetheless, the researchers discovered an elevated danger of kidney most cancers within the GLP-1RA group in contrast with metformin.
“On this examine of sufferers with T2D [type 2 diabetes] who have been cancer-free at baseline, taking GLP-1RAs in contrast with insulin was related to a decrease danger of 10 of 13 OACs,” mentioned the researchers. “The potential cancer-preventative results of OACs by GLP-1RAs warrant additional long-term research in addition to research of particular person newer and presumably more practical antidiabetic and weight reduction brokers … Research are additionally warranted to guage the preventive results of those brokers on non-OACs.”
The researchers don’t supply a mechanism by which GLP-1RAs exert their cancer-inhibiting results however say that their findings relating to kidney and breast most cancers require additional examine. To their data, there have been no prior stories of kidney cancers with using GLP-1RAs, however they urge continued monitoring of sufferers taking this class of medicine. The dearth of impact of GLP-1RAs on breast most cancers must be investigated to find out the influence of longer-term remedy and to raised perceive the connection between GLP-1RAs and estrogen metabolism.
The researchers notice the examine’s limitations. As a retrospective observational examine of affected person well being data, it has inherent limitations, together with over-, under-, and misdiagnosis and biases. Though an intensive checklist of variables was managed for, these limitations and biases couldn’t be eradicated absolutely. Additionally, due to the lack of know-how relating to sufferers’ adherence to remedy, the researchers used an ‘intention-to-treat’ (that’s, remedy prescriptions) for comparability, whether or not or not people adhered to their prescribed remedy regime.
The examine was printed within the journal JAMA Community.
Supply: CWRU College of Drugs through Scimex
